XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 27.23

+3.2%

Jan 7 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Bluegreen who wrote (10722)	7/11/1999 12:38:00 AM
From: aknahow	of 17367

Review material. FOR RELEASE: March 9, 1999 XOMA Continues Patient Enrollment in NEUPREX® Meningococcemia Phase III Pivotal Trial Berkeley, CA -- March 9, 1999 -- XOMA Ltd. (Nasdaq: XOMA) today announced that an independent Data Safety Monitoring Board (DSMB) has advised the Company that it should continue to enroll patients in its Phase III NEUPREX® meningococcemia trial until the prespecified overall mortality number is met. The DSMB has not identified any safety issues. The double-blinded, placebo-controlled pivotal trial has enrolled 370 patients to date in hospitals in the United States and United Kingdom. <<<<<<<<<<<<< This means the 90 day lookback for 370 occured June 9. All those accrued from March 9 thru April 13 will have also completed the 90 day lookback period. We also know that from March 9 thru April 13 the accural rate was declining, week by week. Would guess that of the 25 accrued from March 9 thru April 13 about 2/3 of the 25 were accrued with 1/3 or only 8 in the final month. Say even 10, this would still mean 15 more could be added to the 370 to produce a total of 385 who probably completed the 90 day lookback period by July 13.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next